Free Trial

Arcutis Biotherapeutics (ARQT) Earnings Date, Estimates & Call Transcripts

Arcutis Biotherapeutics logo
$28.12 +0.73 (+2.65%)
As of 03:25 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Arcutis Biotherapeutics Earnings Summary

Arcutis Biotherapeutics issued Q3 2026 earnings on November 4, 2026, reporting an EPS of $0.06, which missed analysts' consensus estimates of $0.18 by $0.12. Quarterly revenue was reported to be $143.92 million, above analysts' expectations of $142.59 million. With a trailing EPS of $0.21 and a P/E Ratio of 133.93, Arcutis Biotherapeutics' earnings are expected to grow 203.57% next year, from $0.28 to $0.85 per share.

Latest Q3
Earnings Date
Nov. 4Estimated
Consensus EPS
(Nov. 4)
$0.18
Actual EPS
(Nov. 4)
$0.06 Missed By -$0.12
Actual Revenue
(Nov. 4)
$143.92M

Q3 2026 Earnings Resources

Get Arcutis Biotherapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arcutis Biotherapeutics and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

ARQT Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ARQT Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Arcutis Biotherapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20261-$0.08-$0.08-$0.08
Q2 20261$0.04$0.04$0.04
Q3 20261$0.17$0.17$0.17
Q4 20261$0.16$0.16$0.16
FY 20264$0.29$0.29$0.29
Q1 20271$0.07$0.07$0.07
Q2 20271$0.14$0.14$0.14
Q3 20271$0.22$0.22$0.22
Q4 20271$0.24$0.24$0.24
FY 20274$0.67$0.67$0.67

Arcutis Biotherapeutics Earnings History by Quarter

Report Date
0 Results
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026$0.18$0.06 -$0.12$0.06$142.59M$143.92M
8/5/2026Q2 2026$0.0551$0.11+$0.0549$0.11$118.85M$129.86M
5/6/2026Q1 2026-$0.02-$0.09 -$0.07-$0.09$103.68M$105.40M
2/25/2026Q4 2025$0.03$0.13+$0.10-$110.79M$129.50M
10/28/2025Q3 2025-$0.10$0.06+$0.16$0.06$86.69M$99.22M
8/6/2025Q2 2025-$0.18-$0.13+$0.05-$0.13$72.70M$81.50M
5/6/2025Q1 2025-$0.21-$0.20+$0.01-$0.20$64.80M$65.85M
2/25/2025Q4 2024-$0.28-$0.09+$0.19-$0.09$60.52M$71.36M

Arcutis Biotherapeutics Earnings - Frequently Asked Questions

Arcutis Biotherapeutics (NASDAQ:ARQT) last announced its quarterly earning data on Wednesday, November 4, 2026. Learn more on ARQT's earnings history.

In the previous quarter, Arcutis Biotherapeutics (NASDAQ:ARQT) missed the analysts' consensus estimate of $0.18 by $0.12 with a reported earnings per share (EPS) of $0.06. Learn more on analysts' earnings estimate vs. ARQT's actual earnings.

The conference call for Arcutis Biotherapeutics' latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Arcutis Biotherapeutics' latest earnings report can be read online.
Read Transcript

Arcutis Biotherapeutics (NASDAQ:ARQT) has a recorded annual revenue of $376.07 million.

Arcutis Biotherapeutics (NASDAQ:ARQT) has a recorded net income of -$16.14 million. ARQT has generated $0.21 earnings per share over the last four quarters.

Arcutis Biotherapeutics (NASDAQ:ARQT) has a trailing price-to-earnings ratio of 133.93 and a forward price-to-earnings ratio of 32.95.

Arcutis Biotherapeutics' earnings are expected to grow from $0.28 per share to $0.85 per share in the next year, which is a 203.57% increase.


Earnings data for NASDAQ:ARQT is sourced from Fiscal.ai, with the most recent quarter reported on 11/4/2026. New results are added as companies report their earnings.
From Our Partners